SEP 9, 2026 · JOURNAL ARTICLE
Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib
Frontiers in Immunology
A single case report with sustained disease response offers an anecdotal observation but lacks the controlled design, comparator, or sample size needed to establish efficacy; the authors explicitly acknowledge limited evidence requiring validation.
Reported
Duration of no radiographic evide…45 months
Overall survival14 years